This new report is a five-country strategic analysis of the major business opportunities emerging in the automated microbiology market during the next five years.
The report is available by section, and can be customized to specific information needs and budget. The report examines key trends in major European countries (France, Germany, Italy, Spain, UK); reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for molecular diagnostic, microbial identification, antibiotic susceptibility, blood culture, urine screening and immunodiagnostic procedures, as well as over 100 infectious disease tests by assay, application, market segment, and country; profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers.
The level of automation in the microbiology laboratory has been lagging behind that of other major clinical laboratory segments, such as chemistry and hematology. The slow acceptance of the technology is in part due to the complexity of developing automation suitable for microbiology tests.
The introduction of automated microbiology instrumentation has been delayed by a number of intrinsic and technical problems. The diffusion of automated microbiology systems, once the technology was developed, has not matched that of other automated laboratory technologies. The acquisition of automation in microbiology has been slowed by forces less easily identifiable than the effects of various reimbursement plans. Some laboratorians still believe that current instrumentation is not the ultimate technology and expect better automation on the horizon.
The driving force behind the need for rapid reporting of microbiological test results is the clinical relevance in a time of financial austerity, a time when cost and health care effectiveness to the patient and diagnostician looms ever larger, and where after-the-fact results at high expense are coming under severe scrutiny worldwide.
This comprehensive five-country report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding microbiology market, in evaluating emerging opportunities and developing effective business strategies.
France, Germany, Italy, Spain, UK
Supplier Shares, Sales and Volume Forecasts
- Sales and market shares of major suppliers of microbiology products, by country and individual test.
- Five-year test volume and sales forecasts for over 100 microbiology assays by country.
- Test volume estimates by method (molecular, serology/immunodiagnostics, culture/microscopy).
European Market Overview
- Review of the market dynamics, trends, structure, size, growth and major suppliers by country.
- Estimated universe of laboratories performing microbiology testing by country.
- Specimen, test volume and sales forecasts by country.
Business Opportunities and Strategic Recommendations
- Emerging opportunities for new analyzers, reagents kits, IT and other products with significant market appeal during the next five years.
- Design criteria for decentralized testing products.
- Alternative market penetration strategies
- Potential market entry barriers and risks.
- Sterile Fluids: Blood, Serum, CSF
- Throat Swabs, Respiratory Secretions
- Genital Secretions
- Antibiotic Susceptibility
- Urine Screening
- Blood Cultures
Review of Major Automated Systems
- Review of major automated molecular diagnostic, multipurpose, specialized, microbial identification, antibiotic susceptibility, blood culture, urine screening, and immunodiagnostic analyzers marketed by Abbott, Alifax, BD, Beckman Coulter/Danaher, Biolog, bioMerieux, Bio-Rad, Cepheid, Curetis, GenMark, Hologic, HTG, Labsystems, Qiagen, Roche, Siemens Healthineers, Sy-Lab, Sysmex, Tecan, Thermo Fisher, Tosoh and other suppliers.
Infectious Diseases Analyzed in the Report
AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter, Candida, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium, Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea, Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes Influenza, Legionella, Lyme Disease, Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps, Mycoplasma, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus , Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia and others.
- Assessment of molecular diagnostic, monoclonal antibody, immunoassay, and other technologies and their potential applications for the microbiology market.
- Global listings of companies developing or marketing microbiology products by individual test.
- Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.
- The companies analyzed in the report include:
- Abbott Laboratories
- Agilent Technologies
- Beckman Coulter/Danaher
- Eiken Chemical
- Instrumentation Laboratory/Werfen
- Kyowa Medex
- Ortho-Clinical Diagnostics
- Quest Diagnostics
- Siemens Healthineers
- Thermo Fisher
Contains 600 pages and 257 tables